Space Details:

Key	GD
Name	GUMDROP
Description
Created by	shillinj (Feb 22, 2012)

Available Pages:

Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
GUMDROP - Genitourinary Multidisciplinary DC Regional Oncology Project (GUMDROP)
- Bladder
  - 1. Adjuvant
    - JHMI J1181 A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
    - JHMI - J1346 - A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression - Hoosier Oncology Group GU12-157
    - JHMI R0926 Phase II, Stage T1 Bladder Cancer, Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
  - 1. Metastatic
    - CALGB 90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma
    - GWU - A Phase 2 Study Evaluating the Efficacy of Docetaxel in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder
    - JHMI - CALGB90601 - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
    - JHMI ECALGB90601 - A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin and placebo in patients with advanced Transitional Cell Carcinoma
    - JHMI J1154 Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab or IMC18F1 or Without Investigational Therapy as Second line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder
    - NCI 11-C-0130 A Phase II Study of TRC105 in Adults With Advanced or Metastatic Urothelial Carcinoma
    - NCI 11-C-0140 A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced or Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
    - NCI 11-C-xxx Multi-Center Phase Ib,II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
    - NCT01437488 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
    - NCT01688999 A Phase II Study of Cabozantinib (XL184) in Patients With Advanced Metastatic Urothelial Carcinoma
    - UMD - A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
    - UMD - Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
- Prostate
  - 1. Localized
    - A phase 2, randomized, 3-arm study of abiraterone acetate alone, AA plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
    - A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer
    - CALGB 70807 The Mens Eating and Living (MEAL) Study. A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
    - CUA - A Phase 2 multicenter prospective open label 2-dose level clinical safety and efficacy evaluation of injection of NX-1207 for the treatment of low risk, localized (T1c) Prostate Cancer.
    - CUA - A Phase 2 multi-center prospective open label 2-dose level clinical safety and efficacy evaluation of injection of NX-1207 for the treatment of low risk, localized (T1c) Prostate Cancer.
    - GWU - A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy
    - INOVA - A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
    - INOVA - A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
    - JHMI - A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a GM-CSF-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy
    - JHMI - Multiparametric MRI for Assessing Radiotherapy Treatment Response of Prostate Cancer
    - NCI 09-C-0120 An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
    - NCI 11-c-0098 Evaluation of Ferumoxytol enhanced MRI for the detection of lymph node involvement in CaP
    - NCI 11-C-0158 MR Image Guided Focal Therapy in Prostate Cancer
    - NCI 13-c-0119 Evaluation of local response of CaP to irradiation using multiparametric MRI & MR guided biopsies
    - NCI 09-C-0120 An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
    - NCI - A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
    - new study
    - Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy
    - Phase II Study to Evaluate the Efficacy of Intensity Modulated Radiation Therapy with Hypofractionated Radiosurgical Boosts in the Treatment of Clinically Localized Prostate Cancer
    - Prospective Endoscopic Safety Evaluation of Late Rectal Mucosal Injury Following CyberKnife Radiosurgery for Clinically Localized Prostate Cancer
    - RTOG 0831 A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer
    - Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients with High Risk localized Prostate Cancer
    - UMD - Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer. A Phase III Randomized Trial
    - UMD - A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
    - UMD - A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy
    - UMD - A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy
    - UMD - Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
    - WHC - CALGB 70807 The Mens Eating and Living (MEAL) Study. A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
    - WRNMMC - A Multicenter Clinical Study of the Sonablate 500 (Sonablate) for the Treatment of Locally Recurrent Prostate Cancer With HIFU
    - WRNMMC - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    - WRNMMC - A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
    - WRNMMC - Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
    - WRNMMC - The Men's Eating and Living (MEAL) Study - A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
  - 2. Biochemical recurrence
    - AOH - IMAAGEN A Multicenter, Open label, Single arm, Phase II study of Abiraterone Acetate plus Prednisone in subjects with Advanced Prostate Cancer without Radiographic Evidence of Metastatic Disease
    - A phase 2, randomized, 3-arm study of abiraterone acetate alone, AA plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
    - A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed ONly Radiation (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostectomy
    - A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and ADT in Men with Non-Metastatic Prostate Cancer and a Rising PSA After Primary Therapy
    - A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
    - Efficacy and Safety of oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer- Randomized, Dose-Ranging Study of KLTc Gelcap on PSA Doubling Time Among Men with Rising PSA
    - HUH - Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy
    - JHMI 07122 Randomized, Controlled Phase II Study of Valproic Acid in Patients With Non-metastatic Biochemical Progression of Prostate Cancer
    - JHMI J1159 An Open Label, Phase 1 and 2 Safety, Pharmacokinetic, and Proof of Concept Study of ARN 509 in Patients with Progressive Advanced Castration Resistant Prostate Cancer
    - Multimodality Therapy (docetaxel, sunitinib, and external beam radiotherapy) for Recurrent High Risk Prostate Cancer- A Phase II Study
    - NCI 07-C-0107 A randomized Phase II trial combining vaccine therapy with PROSTVAC-TRICOM and Flutamide, vs Flutamide alone in men with androgen insensitive, non metastatic (D0.5) prostate cancer.
    - Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy
    - Phase II, Randomized Study of MK-2206 Bicalutamide Combination in Patients with Rising PSA at High-Risk of Progression After Primary Therapy
    - Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naive Recurrent Prostate Cancer
    - Randomized Phase II trial of short-course androgen deprivation therapy with and without bevacizumab for PSA recurrence of prostate cancer after definitive local therapy
  - 3. Metastatic, hormone-sensitive
    - A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer
    - CALGB 90202 A RANDOMIZED DOUBLE-BLIND, PLACEBO CONTROLLED PHASE III STUDY OF EARLY VERSUS STANDARD ZOLEDRONIC ACID TO PREVENT SKELETAL RELATED EVENTS IN MEN WITH PROSTATE CANCER METASTATIC TO BONE
    - CHAARTED - E3105 - ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
    - ECOG E3805 CHAARTED ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
    - TAXYNERGY
    - WHC - A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
    - WRNMMC - ARMOR2 A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
    - WRNMMC - ARMOR2 - A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
  - 4. Metastatic, castration-resistant
    - A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
    - AOH - FIRSTANA- Randomized, Open Label, Study Comparing Cabazitaxel at 25 mg per m2 and at 20 mg per m2 every 3 weeks to Docetaxel in Combination with Prednisone in Patients with mCRPC not Pretreated with Chemotherapy
    - AOH - PROSELICA - Randomized, open label study comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 every 3 weeks in combination with Prednisone for the treatment of mCRPC previously treated with Docetaxel containing Regimen
    - A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)
    - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with metastatic Castrate-Resistant Prostate Cancer
    - A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of ARQ 197 (tivatinib) in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
    - A Randomized, Open-Label, Phase 2 Trial of of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer
    - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
    - CUA - A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects With Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease
    - CUA - A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy
    - CUA - A Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
    - GUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    - GWU - A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer
    - HUH - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    - JHMI J0874 A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination with the HDAC Inhibitor Vorinostat in Patients with Metastatic Prostate Cancer
    - JHMI J0915 Phase I, First in Human Study of Orally Administered AMG 900 in Adult Subjects with Advanced Solid Tumors
    - JHMI J1048 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer
    - JHMI J1066 A Phase I and IIa Study of Safety and Efficacy of Alpharadin with docetaxel in patients with bone metastases from castration-resistant prostate cancer
    - JHMI J1078 A Phase 2 Randomized Study of Cediranib Alone Compared with the Combination of Cediranib plus Dasatinib in Docetaxel Resistant, Castration Resistant Prostate Cancer
    - JHMI J1103 Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer
    - JHMI J1106 A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel aka TAK-700 Plus Prednisone With Placebo Plus Prednisone in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    - JHMI J1128 A Phase II Trial of STA 9090 in Patients with Metastatic Castration Resistant Prostate Cancer Pretreated with Docetaxel Based Chemotherapy
    - JHMI J1156 Randomized, Open Label Phase 3 Study Comparing Cabazitaxel at 20 mg per m2 and at 25 mg per m2 Every 3 Weeks in Combination with Prednisone for mCRPC Previously Treated with a Docetaxel Containing Regimen
    - JHMI J1159 An Open-Label, Phase 1 and 2 Safety, Pharmacokinetic, and Proof-of-Concept Study of ARN-509 in Patients with Progressive Advanced Castration Resistant Prostate Cancer
    - JHMI J1159 A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects with Advanced Prostate Cancer
    - JHMI J1249 A Phase Ib/II Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
    - JHMI J09113 An Open-Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 in Patients with Advanced Solid Tumors
    - JHMI J09121 A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men with CRPC
    - JHMI J11151 A Phase 3, randomized, double-blind, controlled trial of cabozantinib -XL184- vs. mitoxantrone plus prednisone in men with previously treated symptomatic CRPC
    - NCI 07-C-0106 A randomized phase 2.5 study of 153Sm-EDTMP (Quadramet) with or without a PSA-TRICOM vaccine in men with androgen-insensitive metastatic prostate cancer
    - NCI 09-C-0195 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
    - NCI 10-C-0062 A Phase I,II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
    - NCI 11-C-0262 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V,F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer
    - NCI 12-c-0080 NaF PET/CT repeatability, responsiveness & response assessment in mCRPC to bone w/ either docetaxel or AR-directed therapies
    - NCI 12-C-0079 A Phase II Study of AMG 386 and abiraterone in metastatic castration resistant prostate cancer
    - NCI 12-C-0204 Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
    - NCI 13-C-0146 A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    - NCI 13-C-0146 A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
    - Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
    - Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer (E1809)
    - title
    - title1
    - Trial to Compare the Efficacy of Ipilimumab in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naive Castration Resistant Prostate Cancer
    - UMD - A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer
    - UMD - A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
    - UMD - A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy
    - UMD - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    - UMD - A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
    - UMD - A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
    - UMD - A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
    - UMD - Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease
  - 5. Non-therapeutic
    - A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (JHUH)
    - A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer (GUH)
    - Evaluation of 18F-DCFBC PSMA-based PET imaging for Detection of Metastatic Prostate Cancer
    - HUH - Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
    - NCI 13-c-0145 A Pilot Study of Eovist (gadoxetate) enhanced MRI for the detection of prostate cancer
    - Understanding mechanisms of response and resistance to androgen-directed therapies in men with advanced prostate cancer through interrogation of tumor biopsies (with a focus on androgen receptor variants)
- Renal
  - 1. General
    - AOH - EVEREST - EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
    - A Phase 3 Trial of Everolimus for Renal Cell Ensuing Surgical Therapy
    - GUH - EVEREST - EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
    - JHMI J1099 A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephrectomy
    - NCI 08-C-0020 A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors
    - test
      - test 2
    - UMD - EVEREST - EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
    - VEG113387 A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy
    - WHC - EVEREST - EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
  - 2. Metastatic
    - A Phase 2 Randomized Study of Dalantercept in Combination With Axitinib Compared to Axitinib Alone as Second Line Treatment in Patients With Metastatic Renal Cell Carcinoma
    - A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
    - CALGB 90802 Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors
    - E7080-G000-205 A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
    - GUH - Randomized Phase II Study Comparing Cabozantinib (NSC
    - GWU - Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
    - IMA901 301 A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-Line therapy for Advanced and Metastatic Renal Cell Carcinoma
    - JHMI E1808 A Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
    - JHMI J0841 Phase I and II Study of High Dose IL2 -Aldesleukin- in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic RCC
    - JHMI J1180 An Exploratory Study to Investigate the Immunomodulatory Activity of Various Dose Levels of Anti Programmed Death 1 Antibody, BMS-936558, in Metastatic Clear Cell RCC
    - JHMI J1287 A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
    - JHMI J4805 A Randomized Phase II study to determine the effect of 2 different doses of AVE0005 in patients with metastatic RCC
    - JHMI J11136 A Phase 1 Study of BMS936558 Plus Sunitinib or Pazopanib in Subjects with Metastatic Renal Cell Carcinoma
    - NCI 09-C-0057 A Phase II Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma
    - NCI 10-C-0114 A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
    - Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
    - Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy
    - UMD - An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    - WHC - Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
    - WHC - Randomized Phase II Study Comparing Cabozantinib (NSC
JHMI 0858 Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer
Multimodaliaty Therapy incl. docetaxel, sunitinib, and external beam radiotherapy, for Recurrent High Risk Prostate Cancer. A Phase II Study
NCI 05-C-0241 A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer
NCI 11-C-0247 A randomized phase II study of L-BLP25 in combination with standard androgen deprivation therapy and radiation therapy for newly diagnosed, high risk prostate cancer patients.
NCI-11-C-0262 - A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V,F ± GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer